Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group/Crossover Thorough QT/QTc Study to Evaluate the Effect of a Therapeutic Dose and a Supra-therapeutic Dose of VI-0521 on Cardiac Repolarization in Healthy Male and Female Volunteers
NCT00839891 is registered in ClinicalTrials.gov with VIVUS LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group/Crossover Thorough QT/QTc Study to Evaluate the Effect of a Therapeutic Dose and a Supra-therapeutic Dose of VI-0521 on Cardiac Repolarization in Healthy Male and Female Volunteers
- Lead sponsor
- VIVUS LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2009
- Completion date
- April 30, 2009
- Enrollment
- 112 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.